EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Topical Esomeprazole for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer: Protocol for a Phase 2 Randomized Controlled Trial

Aaron Cheng iD, Pavela Bambekova iD, Yohannes T Ghebre iD, Mark D Bonnen iD, Timothy Wagner iD, Sandra Osswald iD, Carol Jenkins iD, Pia Roperes iD, Shraddha Dalwadi iD

JMIR Research Protocols · 02.11.2026 · 15 · e91035

DOI: 10.2196/91035 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, online erschienen am 02.11.2026. Verfasst von Aaron Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Long School of Medicine, The University of Texas Health at San Antonio, San Antonio, TX, United States. Hauptthemen laut MEDLINE: Radiodermatitis, Head and Neck Neoplasms, Esomeprazole. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radiation dermatitis (RD) is a common and clinically significant toxicity affecting the majority of patients undergoing external beam radiation therapy, particularly those treated for head and neck cancer (HNC). RD can impair quality of life, limit treatment intensity, and compromise oncologic outcomes; yet, there is no established standard-of-care for its prevention or management. Preclinical studies suggest that a topically reformulated proton pump inhibitor (PPI), esomeprazole (Dermaprazole), has antioxidant, anti-inflammatory, and antifibrotic properties that may mitigate radiation-induced skin injury.

Objective

This phase 2 randomized controlled trial aims to evaluate the potential safety, feasibility, and efficacy of prophylactic topical Dermaprazole compared with standard supportive care (Aquaphor) in reducing the incidence and severity of clinically significant RD in patients with HNC receiving definitive chemoradiation.

Methods

This is a prospective, single-center, randomized controlled trial with a 2:1 allocation ratio. A total of 45 adults (≥18 y) with biopsy-confirmed head and neck malignancy planned to receive definitive chemoradiation of at least 66 Gy will be enrolled. Participants will be randomized to receive twice-daily topical Dermaprazole or Aquaphor beginning at computed tomography (CT) simulation and continuing through 2 weeks after completion of radiation therapy. The primary outcome is the rate and severity of RD, assessed weekly during treatment using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5 by the treating radiation oncologist, with blinded dermatologic assessment based on standardized medical photography. Feasibility outcomes include accrual rate, treatment compliance, and questionnaire completion rates. Secondary outcomes include time to onset and healing of grade ≥2 RD, quality of life assessed using the Skindex-16 instrument, radiation dose thresholds associated with dermatitis, and changes in inflammatory biomarkers (C-reactive protein, tumor necrosis factor-α, interleukin [IL]-1β, and IL-6). More specifically, secondary outcomes will be assessed through serial CTCAE version 5 evaluations for onset and healing, Skindex16 questionnaires for quality of life, radiation dose-volume parameters for dermatitis thresholds, and serum inflammatory marker concentration measurements before, during, and after treatment.

Results

The study began in June 2022 and has completed enrollment. Data analysis will commence following completion of data collection, with results expected to be published by 2027.

Conclusions

Should Dermaprazole demonstrate efficacy in reducing RD in patients undergoing radiation therapy, it may offer an alternative or adjunctive treatment option for the prevention and management of RD, potentially reducing treatment-related morbidity and improving patients’ quality of life during radiotherapy. Trial Registration ClinicalTrials.gov NCT04865731; https://clinicaltrials.gov/study/NCT04865731 International Registered Report Identifier (IRRID) DERR1-10.2196/91035

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiodermatitisHead and Neck NeoplasmsEsomeprazoleHumansAdministration, TopicalClinical Trials, Phase II as TopicFemaleRandomized Controlled Trials as TopicProspective StudiesMaleAdultQuality of Life

Stichwörter der Autor:innen

administrationdrug repurposingesomeprazolehead and neck neoplasmsoncologyproton pump inhibitorsradiation dermatitisradiodermatitistopical

Substanzen

Esomeprazole

Autor:innen und Institutionen

  • Long School of Medicine, The University of Texas Health at San Antonio, San Antonio, TX, United States.
  • Division of Dermatology, University of Texas Health at San Antonio, San Antonio, TX, United States.
  • Department of Radiation Oncology, The University of Texas Health at San Antonio, San Antonio, TX, United States.
  • School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Division of Dermatology, The University of Texas Health at San Antonio, San Antonio, TX, United States.

ORCID-Profile: Aaron Cheng, Pavela Bambekova, Yohannes T Ghebre, Mark D Bonnen, Timothy Wagner, Sandra Osswald, Carol Jenkins, Pia Roperes, Shraddha Dalwadi

Förderung

  • NCI NIH HHS

Zitieren

APA

Cheng, A., Bambekova, P., Ghebre, Y. T., Bonnen, M. D., Wagner, T., Osswald, S., Jenkins, C., Roperes, P., & Dalwadi, S. (2026). Topical Esomeprazole for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer: Protocol for a Phase 2 Randomized Controlled Trial. JMIR Research Protocols, 15, e91035. https://doi.org/10.2196/91035

Vancouver

Cheng A, Bambekova P, Ghebre YT, Bonnen MD, Wagner T, Osswald S, et al. Topical Esomeprazole for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer: Protocol for a Phase 2 Randomized Controlled Trial. JMIR Research Protocols. 2026;15:e91035. doi:10.2196/91035

BibTeX
@article{Cheng2026,
  author = {Cheng, Aaron and Bambekova, Pavela and Ghebre, Yohannes T and Bonnen, Mark D and Wagner, Timothy and Osswald, Sandra and Jenkins, Carol and Roperes, Pia and Dalwadi, Shraddha},
  title = {Topical Esomeprazole for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer: Protocol for a Phase 2 Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e91035},
  doi = {10.2196/91035}
}
Kostenlos starten →